tildrakizumab-asmn (Ilumya)
tildrakizumab-asmn is an FDA-licensed reference biologic from Sun Pharmaceutical Industries Limited. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2018
Reference approved
Reference product
Ilumya tildrakizumab-asmn
Sun Pharmaceutical Industries Limited
- Approved
- Mar 20, 2018
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for tildrakizumab-asmn, in chronological order.
Reference approval
Approval date of the reference tildrakizumab-asmn product.
8 yr 4 mo ago
Frequently asked questions
Are there biosimilars approved for tildrakizumab-asmn (Ilumya)?
No 351(k) biosimilars or interchangeable biosimilars referencing tildrakizumab-asmn are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.